Glutamine for the treatment of vincristine-induced neuropathy in children and adolescents with cancer.

ABSTRACT:

Background

Vincristine is an integral treatment component of many childhood tumors with potentially dose-limiting sensory and/or motor neuropathy. Results from a pilot study on the incidence of vincristine-induced peripheral neuropathy (VIPN) as well as the efficacy and safety of glutamine in reducing signs and symptoms of VIPN in children with cancer are presented.

Methods

Fifty-six patients between the ages of 5-21 with newly diagnosed leukemia, lymphoma, extracranial solid tumor or medulloblastoma and expected to receive a minimum cumulative dose of 6 mg/m² of vincristine over a 30-week period were eligible. Patients' neurological functioning was monitored every 3 weeks using clinical history, exam, and assessment of motor functioning. Upon identification of ne

SUBMITTER: Sands S 

PROVIDER: S-EPMC5598352 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature